Search

Your search keyword '"Bombardieri, Stefano"' showing total 1,121 results
Start Over Author "Bombardieri, Stefano"
1,121 results on '"Bombardieri, Stefano"'

151. Correspondence between salivary proteomic pattern and clinical course in primary Sjögren syndrome and non-Hodgkin's lymphoma: a case report

Author

Baldini Chiara, Giusti Laura, Ciregia Federica, Da Valle Ylenia, Giacomelli Camillo, Donadio Elena, Ferro Francesco, Galimberti Sara, Donati Valentina, Bazzichi Laura, Bombardieri Stefano, and Lucacchini Antonio

Subjects
primary Sjögren's Syndrome, B-cell non-Hodgkin's lymphoma, proteomic analysis, Medicine
Abstract

Abstract Background In the last years human proteomic has represented a promising tool to promote the communication between basic and clinical science. Methods To explore the correspondence between salivary proteomic profile and clinical response, herein, we used a proteomic approach to analyse the whole saliva of a patient with primary Sjögren's Syndrome (pSS) and non-Hodgkin's-MALT type parotid lymphoma before, during and after a standard treatment with cyclophosphamide (CTX) and rituximab (RTX). To identify any discriminatory therapeutic salivary biomarker patient's whole saliva was collected at the baseline, after the fourth infusion of rituximab, and on remission and analysed combining two-dimensional electrophoresis (2DE) and MALDI-TOF/TOF mass spectrometry. Results Proteomic results obtained from the comparison of salivary samples indicated several qualitative and quantitative modifications in the salivary expression of putative albumin, immunoglobulin J chain, Ig kappa chain C region, alpha-1-antitrypsin, haptoglobin and Ig alpha-1 chain C region. Conclusion This study suggests that clinical and functional changes of the salivary glands driven by autoimmune and lymphoproliferative processes might be reflected in patients' whole saliva proteins, shedding new light on the potential usefulness of salivary proteomic analysis in the identification of prognostic and therapeutic biomarkers for patients with pSS and non Hodgkin's lymphomas.

Published
2011
Full Text
View/download PDF

152. Systemic lupus erythematosus: state of the art on clinical practice guidelines

Author

Tamirou, Farah, primary, Arnaud, Laurent, additional, Talarico, Rosaria, additional, Scirè, Carlo Alberto, additional, Alexander, Tobias, additional, Amoura, Zahir, additional, Avcin, Tadej, additional, Bortoluzzi, Alessandra, additional, Cervera, Ricard, additional, Conti, Fabrizio, additional, Cornet, Alain, additional, Devilliers, Hervé, additional, Doria, Andrea, additional, Frassi, Micol, additional, Fredi, Micaela, additional, Govoni, Marcello, additional, Houssiau, Frederic, additional, Lladò, Ana, additional, Macieira, Carla, additional, Martin, Thierry, additional, Massaro, Laura, additional, Moraes-Fontes, Maria Francisca, additional, Pamfil, Cristina, additional, Paolino, Sabrina, additional, Tani, Chiara, additional, Tas, Sander W, additional, Tektonidou, Maria, additional, Tincani, Angela, additional, Van Vollenhoven, Ronald F, additional, Bombardieri, Stefano, additional, Burmester, Gerd, additional, Fonseca, João Eurico, additional, Galetti, Ilaria, additional, Hachulla, Eric, additional, Mueller-Ladner, Ulf, additional, Schneider, Matthias, additional, Smith, Vanessa, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Costedoat-Chalumeau, Nathalie, additional

Published
2018
Full Text
View/download PDF

155. Muscle modifications in fibromyalgic patients revealed by surface electromyography (SEMG) analysis

Author

Zirafa Cristina, Giacomelli Camillo, De Feo Francesca, Corbianco Silvia, Rossi Alessandra, Dini Marco, Bazzichi Laura, Ferrari Claudia, Rossi Bruno, and Bombardieri Stefano

Subjects
Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background Several studies have been carried out in order to investigate surface electromyography (SEMG) response on fibromyalgic (FM) patients. Some studies failed to demonstrate differences between FM patients and healthy individuals while others found differences in SEMG parameters. Different muscular region have been analyzed in FM patients and heterogeneity is also produced because of the different ways in which the SEMG technique is used. The aims of this study were to evaluate muscle modifications by SEMG analysis in FM women with respect to a sample of healthy controls and to investigate the relationships between SEMG parameters and the clinical aspects of the disease. Methods SEMG was recorded in 100 FM women (48.10 ± 11.96 yr) and in 50 healthy women (48.60 ± 11.18 yr), from the tibialis anterior and the distal part of vastus medialis muscle during isometric contraction. Initial values and rate of change of median spectral frequency (MDF) and conduction velocity (CV) of the SEMG signal were calculated. The clinical parameters "Fibromyalgia Impact Questionnaire", pain, tender points, tiredness were evaluated and the relationships between these data and the SEMG results were also studied. For the statistical analysis Mann-Whitney test, chi-square test and Spearman correlation were used. Results MDF absolute values and the so-called Fatigue Index (FI) were significantly lower (p < 0.001) in both muscles studied in FM patients (MDF: 93.2 μV; FI: 1.10, 0.89) with respect to healthy controls (MDF: 138.2 μV; FI: 2.41, 1.66) and a smaller reduction in the percentage values of MDF was observed in FM patients vs controls (22% vs 38%). A significant correlation was found between the SEMG parameter decrement of normalized median frequency (MNF) (%) and seriousness of FM (evaluated by means of tender points). Conclusion We have found some interesting muscle modifications in FM patients with respect to healthy controls, regarding MDF, CV and FI values which resulted significantly lower in FM. Patients might have a different fiber recruitment or a possible atrophy of type II fibers suggesting that they are not able to reach muscle relaxation.

Published
2009
Full Text
View/download PDF

156. The Development and Initial Validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus

Author

Gladman, Dafna, Ginzler, Ellen, Goldsmith, Charles, Fortin, Paul, Liang, Matthew, Urowitz, Murray, Bacon, Paul, Bombardieri, Stefano, Hanly, John, Hay, Elaine, Isenberg, David, Jones, John, Kalunian, Kenneth, Maddison, Peter, Nived, Ola, Petri, Michelle, Richter, Martin, Sanchez-Guerrero, Jorge, Snaith, Michael, Sturfelt, Gunnar, Symmons, Deborah, and Zoma, Asad

Published
1996

157. Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study

Author

Vitali, Claudio, Bombardieri, Stefano, Moutsopoulos, Haralampos M., Coll, Joaquin, Gerli, Roberto, Hatron, Pierre Y., Kater, Louis, Konttinen, Yrjo T., Manthorpe, Rolf, Meyer, Olivier, Mosca, Marta, Ostuni, Pierantonio, Pellerito, Raffaele A., Pennec, Yvon, Porter, Stephen R., Richards, Andrea, Sauvezie, Bernard, Schiodt, Morten, Sciuto, Maria, Shoenfeld, Yehuda, Skopouli, Fotini N., Smolen, Josef S., Soromenho, Francisco, Tishler, Moshe, Tomsic, Matija, van de Merwe, Joop P., Yeoman, Christine M., and Wattiaux, Marie J.

Published
1996

161. Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines

Author

Meyer, Alain, Scire, Carlo Alberto, Talarico, Rosaria, Alexander, Tobias, Amoura, Zahir, Avcin, Tadej, Barsotti, Simone, Beretta, Lorenzo, Blagojevic, Jelena, Burmester, Gerd, Cavazzana, Ilaria, Cherrin, Patrick, Damian, Laura, Doria, Andrea, Fonseca, Joao Eurico, Furini, Federica, Galetti, Ilaria, Houssiau, Frederic, Krieg, Thomas, Larosa, Maddalena, Launay, David, Campanilho-Marques, Raquel, Martin, Thierry, Matucci-Cerinic, Marco, Moinzadeh, Pia, Montecucco, Carlomaurizio, Moraes-Fontes, Maria Francisca, Mouthon, Luc, Neri, Rossella, Paolino, Sabrina, Piette, Yves, Rednic, Simona, Tamirou, Farah, Tincani, Angela, Toplak, Natasa, Bombardieri, Stefano, Hachulla, Eric, Mueller-Ladner, Ulf, Schneider, Matthias, Smith, Vanessa, Vieira, Ana, Cutolo, Maurizio, Mosca, Marta, Cavagna, Lorenzo, Meyer, Alain, Scire, Carlo Alberto, Talarico, Rosaria, Alexander, Tobias, Amoura, Zahir, Avcin, Tadej, Barsotti, Simone, Beretta, Lorenzo, Blagojevic, Jelena, Burmester, Gerd, Cavazzana, Ilaria, Cherrin, Patrick, Damian, Laura, Doria, Andrea, Fonseca, Joao Eurico, Furini, Federica, Galetti, Ilaria, Houssiau, Frederic, Krieg, Thomas, Larosa, Maddalena, Launay, David, Campanilho-Marques, Raquel, Martin, Thierry, Matucci-Cerinic, Marco, Moinzadeh, Pia, Montecucco, Carlomaurizio, Moraes-Fontes, Maria Francisca, Mouthon, Luc, Neri, Rossella, Paolino, Sabrina, Piette, Yves, Rednic, Simona, Tamirou, Farah, Tincani, Angela, Toplak, Natasa, Bombardieri, Stefano, Hachulla, Eric, Mueller-Ladner, Ulf, Schneider, Matthias, Smith, Vanessa, Vieira, Ana, Cutolo, Maurizio, Mosca, Marta, and Cavagna, Lorenzo

Abstract

Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidelines (CPGs) have been proposed for IIMs, but they are sparse and heterogeneous. This work aimed at identifying: i) current available CPGs for IIMs, ii) patients' and clinicians' unmet needs not covered by CPGs. It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union's Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. iii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iv) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. Yet, only half of these CPGs were evidence-based. Crucial unmet needs were identified both by patients and clinicians. In particular, there was a lack of large multidisciplinary working group and of patients' preferences. The following fields were not or inappropriately targeted: diagnosis; management of extra-muscular involvements other than skin; co-morbidities and severe manifestations.

Published
2018

162. Sensitivity and specificity of tests for ocular and oral involvement in Sjogren's syndrome

Author

Vitali, Claudio, Moutsopoulos, Haralampos M., and Bombardieri, Stefano

Subjects
Sjogren's syndrome -- Diagnosis, Health
Abstract

Tests that detect abnormalities in the eye and salivary glands are the most reliable tools for diagnosing Sjogren's Syndrome. Sjogren's Syndrome refers to a group of symptoms that are sometimes associated with rheumatoid arthritis and systemic lupus erythematosus. Common symptoms include dry mouth, dry eyes and enlarged parotid glands. An analysis of the diagnostic accuracy of various tests revealed that Schirmer's-I-test (ScT) and rose Bengal score (RBS) were the most accurate tests for evaluating symptoms in the eye related to Sjogren's. Salivary gland scintigraphy (SGS), parotid sialography (PS), minor salivary gland biopsy (MSGB), and unstimulated whole saliva collection (UWSC) were the most accurate tests for the oral symptoms.

Published
1994

163. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

Author

Seror, Raphaèle, Theander, Elke, Brun, Johan G, Ramos-Casals, Manel, Valim, Valeria, Dörner, Thomas, Bootsma, Hendrika, Tzioufas, Athanasios, Solans-Laqué, Roser, Mandl, Thomas, Gottenberg, Jacques-Eric, Hachulla, Eric, Sivils, Kathy L, Ng, Wan-Fai, Fauchais, Anne-Laure, Bombardieri, Stefano, Valesini, Guido, Bartoloni, Elena, Saraux, Alain, Tomsic, Matija, Sumida, Takayuki, Nishiyama, Susumu, Caporali, Roberto, Kruize, Aike A, Vollenweider, Cristina, Ravaud, Philippe, Vitali, Claudio, Mariette, Xavier, Bowman, Simon J, EULAR Sjögren's Task Force, Service de rhumatologie, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Department of Rheumatology, Lund University [Lund], Klinik für Dermatologie, Venerologie und Allergologie, Department of Pathophysiology, Medical School, University of Athens, Immuno-Rhumatologie Moléculaire, Université de Strasbourg ( UNISTRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Lille, Droit et Santé, University of Northumbria at Newcastle [United Kingdom], Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Department of Internal Medicine, Lupus Clinic, Sapienza University [Rome], Immunologie et Pathologie ( EA2216 ), Université de Brest ( UBO ) -IFR148, Centre d'Investigation Clinique ( CIC - Brest ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Faculty of Chemistry and Chemical Technology, University of Ljubjana, University of Tsukuba, Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques ( CRESS - U1153 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Department of Internal Medicine and section of Rheumatology, Villamarina Hospital, Immunologie des Maladies Virales et Autoimmunes ( IMVA - U1184 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques (CRESS - U1153), Université Paris Descartes - Paris 5 (UPD5)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Sorbonne Paris Cité (USPC), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), University of Ljubljana, Université de Tsukuba = University of Tsukuba, Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), and Translational Immunology Groningen (TRIGR)

Subjects
Male, [SDV]Life Sciences [q-bio], Sjögren's Syndrome, Severity of Illness Index, law.invention, RESPONSIVENESS, Randomized controlled trial, law, EUROPEAN LEAGUE, Immunology and Allergy, Prospective Studies, Disease Activity, Outcomes research, Non-U.S. Gov't, Prospective cohort study, Fatigue, primary Sjögren ’ s syndrome, Research Support, Non-U.S. Gov't, Middle Aged, 3. Good health, Europe, Sjogren's Syndrome, REPORTED INDEX, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Female, Adult, medicine.medical_specialty, Immunology, Pain, Research Support, CONTROLLED-TRIAL, Xerostomia, General Biochemistry, Genetics and Molecular Biology, [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatology, Internal medicine, Severity of illness, Xerophthalmia, medicine, Journal Article, Humans, Validation Studies, RITUXIMAB, Aged, [ SDV ] Life Sciences [q-bio], business.industry, Gold standard, Construct validity, Reproducibility of Results, HEALTH-STATUS INSTRUMENTS, medicine.disease, Physical therapy, Self Report, business, Rheumatism
Abstract

Objectives To validate the two recently developed disease activity indexes for assessment of primary Sjogren's syndrome (SS): the European League Against Rheumatism (EULAR) SS Patient Reported Index (ESSPRI) and the EULAR SS Disease Activity Index (ESSDAI).Methods A prospective international 6-month duration validation study was conducted in 15 countries. At each visit, physicians completed ESSDAI, SS disease activity index (SSDAI), Sjogren's Systemic Clinical Activity Index (SCAI) and physician global assessment (PhGA); and patients completed ESSPRI, Sicca Symptoms Inventory (SSI), Profile of Fatigue and Discomfort (PROFAD) and patient global assessment (PGA). Psychometric properties (construct validity, responsiveness and reliability) were evaluated and compared between scores.Results Of the 395 patients included, 145 (37%) and 251 (64%) had currently active or current or past systemic manifestations, respectively. EULAR scores had higher correlation with the gold standard than other scores (ESSDAI with PhGA: r= 0.59; ESSRPI with PGA: r= 0.70). Correlations between patient and systemic scores were very low (ranging from 0.07 to 0.29). All systemic scores had similar large responsiveness in improved patients. Responsiveness of patient scores was low but was significantly higher for ESSPRI compared with SSI and PROFAD. Reliability was very good for all scores.Conclusions ESSDAI and ESSPRI had good construct validity. All scores were reliable. Systemic scores had a large sensitivity to change in patients whose disease activity improves. Patient scores had a small sensitivity to change, however, significantly better for ESSPRI. Systemic and patient scores poorly correlated, suggesting that they are 2 complementary components that should be both evaluated, but separately.

Published
2014
Full Text
View/download PDF

164. 163 - Crioglobulinemia

Author

ROSSA, ALESSANDRA DELLA, TAVONI, ANTONIO, and BOMBARDIERI, STEFANO

Published
2016

165. Systemic sclerosis: state of the art on clinical practice guidelines

Author

Smith, Vanessa, primary, Scirè, Carlo Alberto, additional, Talarico, Rosaria, additional, Airo, Paolo, additional, Alexander, Tobias, additional, Allanore, Yannick, additional, Bruni, Cosimo, additional, Codullo, Veronica, additional, Dalm, Virgil, additional, De Vries-Bouwstra, Jeska, additional, Della Rossa, Alessandra, additional, Distler, Oliver, additional, Galetti, Ilaria, additional, Launay, David, additional, Lepri, Gemma, additional, Mathian, Alexis, additional, Mouthon, Luc, additional, Ruaro, Barbara, additional, Sulli, Alberto, additional, Tincani, Angela, additional, Vandecasteele, Els, additional, Vanhaecke, Amber, additional, Vanthuyne, Marie, additional, Van den Hoogen, Frank, additional, Van Vollenhoven, Ronald, additional, Voskuyl, Alexandre E, additional, Zanatta, Elisabetta, additional, Bombardieri, Stefano, additional, Burmester, Gerd, additional, Fonseca, João Eurico, additional, Frank, Charissa, additional, Hachulla, Eric, additional, Houssiau, Frederic, additional, Mueller-Ladner, Ulf, additional, Schneider, Matthias, additional, van Laar, Jacob M, additional, Vieira, Ana, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Matucci-Cerinic, Marco, additional

Published
2018
Full Text
View/download PDF

166. Mixed connective tissue disease: state of the art on clinical practice guidelines

Author

Chaigne, Benjamin, primary, Scirè, Carlo Alberto, additional, Talarico, Rosaria, additional, Alexander, Tobias, additional, Amoura, Zahir, additional, Avcin, Tadej, additional, Beretta, Lorenzo, additional, Doria, Andrea, additional, Guffroy, Aurelien, additional, Guimarães, Vera, additional, Hachulla, Éric, additional, Krieg, Thomas, additional, Launay, David, additional, Lepri, Gemma, additional, Moinzadeh, Pia, additional, Müller-Ladner, Ulf, additional, Rednic, Simona, additional, Rodrigues, Ana, additional, Tas, Sander W, additional, Van Vollenhoven, Ronald F, additional, Vieira, Ana, additional, Bombardieri, Stefano, additional, Fonseca, João Eurico, additional, Galetti, Ilaria, additional, Schneider, Matthias, additional, Smith, Vanessa, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Fischer-Betz, Rebecca, additional

Published
2018
Full Text
View/download PDF

167. Relapsing polychondritis: state of the art on clinical practice guidelines

Author

Rednic, Simona, primary, Damian, Laura, additional, Talarico, Rosaria, additional, Scirè, Carlo Alberto, additional, Tobias, Alexander, additional, Costedoat-Chalumeau, Nathalie, additional, Launay, David, additional, Mathian, Alexis, additional, Matthews, Lisa, additional, Ponte, Cristina, additional, Toniati, Paola, additional, Bombardieri, Stefano, additional, Frank, Charissa, additional, Schneider, Matthias, additional, Smith, Vanessa, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Arnaud, Laurent, additional

Published
2018
Full Text
View/download PDF

168. Sjögren’s syndrome: state of the art on clinical practice guidelines

Author

Romão, Vasco C, primary, Talarico, Rosaria, additional, Scirè, Carlo Alberto, additional, Vieira, Ana, additional, Alexander, Tobias, additional, Baldini, Chiara, additional, Gottenberg, Jacques-Eric, additional, Gruner, Heidi, additional, Hachulla, Eric, additional, Mouthon, Luc, additional, Orlandi, Martina, additional, Pamfil, Cristina, additional, Pineton de Chambrun, Marc, additional, Taglietti, Marco, additional, Toplak, Natasa, additional, van Daele, Paul, additional, van Laar, Jacob M, additional, Bombardieri, Stefano, additional, Schneider, Matthias, additional, Smith, Vanessa, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Mariette, Xavier, additional

Published
2018
Full Text
View/download PDF

169. Ehlers-Danlos syndromes: state of the art on clinical practice guidelines

Author

Sulli, Alberto, primary, Talarico, Rosaria, additional, Scirè, Carlo Alberto, additional, Avcin, Tadej, additional, Castori, Marco, additional, Ferraris, Alessandro, additional, Frank, Charissa, additional, Grunert, Jürgen, additional, Paolino, Sabrina, additional, Bombardieri, Stefano, additional, Schneider, Matthias, additional, Smith, Vanessa, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Malfait, Fransiska, additional

Published
2018
Full Text
View/download PDF

170. Antiphospholipid syndrome: state of the art on clinical practice guidelines

Author

Limper, Marteen, primary, Scirè, Carlo Alberto, additional, Talarico, Rosaria, additional, Amoura, Zahir, additional, Avcin, Tadej, additional, Basile, Martina, additional, Burmester, Gerd, additional, Carli, Linda, additional, Cervera, Ricard, additional, Costedoat-Chalumeau, Nathalie, additional, Doria, Andrea, additional, Dörner, Thomas, additional, Fonseca, João Eurico, additional, Galetti, Ilaria, additional, Hachulla, Eric, additional, Launay, David, additional, Lourenco, Filipa, additional, Macieira, Carla, additional, Meroni, Pierluigi, additional, Montecucco, Carlo Maurizio, additional, Moraes-Fontes, Maria Francisca, additional, Mouthon, Luc, additional, Nalli, Cecilia, additional, Ramoni, Veronique, additional, Tektonidou, Maria, additional, van Laar, Jacob M, additional, Bombardieri, Stefano, additional, Schneider, Matthias, additional, Smith, Vanessa, additional, Vieira, Ana, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Tincani, Angela, additional

Published
2018
Full Text
View/download PDF

174. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome

Author

UMC Utrecht, Translationele immunologie, Infection & Immunity, Fisher, Benjamin A., Jonsson, Roland, Daniels, Troy, Bombardieri, Michele, Brown, Rachel M., Morgan, Peter, Bombardieri, Stefano, Ng, Wan Fai, Tzioufas, Athanasios G., Vitali, Claudio, Shirlaw, Pepe, Haacke, Erlin, Costa, Sebastian, Bootsma, Hendrika, Devauchelle-Pensec, Valerie, Radstake, Timothy R., Mariette, Xavier, Richards, Andrea, Stack, Rebecca, Bowman, Simon J., Barone, Francesca, UMC Utrecht, Translationele immunologie, Infection & Immunity, Fisher, Benjamin A., Jonsson, Roland, Daniels, Troy, Bombardieri, Michele, Brown, Rachel M., Morgan, Peter, Bombardieri, Stefano, Ng, Wan Fai, Tzioufas, Athanasios G., Vitali, Claudio, Shirlaw, Pepe, Haacke, Erlin, Costa, Sebastian, Bootsma, Hendrika, Devauchelle-Pensec, Valerie, Radstake, Timothy R., Mariette, Xavier, Richards, Andrea, Stack, Rebecca, Bowman, Simon J., and Barone, Francesca

Published
2017

175. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies

Author

Seror, Raphaèle, Meiners, Petra, Baron, Gabriel, Bootsma, Hendrika, Bowman, Simon J, Vitali, Claudio, Gottenberg, Jacques-Eric, Theander, Elke, Tzioufas, Athanasios, De Vita, Salvatore, Ramos-Casals, Manel, Dörner, Thomas, Quartuccio, Luca, Ravaud, Philippe, Mariette, Xavier, Bartoloni, Elena, Gerli, Roberto, Bombardieri, Stefano, Kallenberg, Cees, Brun, Johan G, Caporali, Roberto, Devauchelle, Valerie, Saraux, Alain, Fauchais, Anne-Laure, Gottenberg, Jacques Eric, Hachulla, Eric, Kruize, Aike A, Mandl, Thomas, Demoulins, Frederic, Bicêtre, Le Kremlin, Montecucco, Carlomaurizio, Ng, Wan-Fai, Praprotnik, Sonja, Tomsic, Matija, Casals, Manel Ramos, Scofield, Hal, Sivils, Kathy L., Laqué, Roser Solans, Sumida, Takayuki, Nishiyama, Sumusu, Valesini, Guido, Valim, Valeria, Vollenweider, Cristina, CHU Cochin [AP-HP], Departement of Oral and Maxillofacial Surgery, Groningen, Univesity of Medical Center Groningen, Education Discours Apprentissages (EDA - EA 4071), Université Paris Descartes - Paris 5 (UPD5), Department of Rheumatology and Clinical Immunology Groningen, University Medical Center Groningen [Groningen] (UMCG), Department of Internal Medicine and section of Rheumatology, Villamarina Hospital, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Rheumatology, Lund University [Lund], Department of Pathophysiology, Medical School, University of Athens, University of Udine and University Hospital of Udine, Laboratory of Autoimmune Diseases Josep Font Barcelona, CELLEX-IDIBAPS Department of Autoimmune Diseases, Barcelona, Klinik für Dermatologie, Venerologie und Allergologie, University of Udine and University Hospital- Udine, Università degli Studi di Udine - University of Udine [Italie], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Régulation de la réponse immune, infection VIH-1 et autoimmunité, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Homéostasie Cellulaire et Pathologies (HCP), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Service de médecine interne, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of biomedical sciences, Universita degli Studi di Padova, University of Northumbria at Newcastle [United Kingdom], University Medical Centre, Faculty of Chemistry and Chemical Technology, University of Ljubjana, University of Tsukuba, Department of Internal Medicine, Lupus Clinic, Sapienza University [Rome], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-CHU Limoges, Université de Tsukuba = University of Tsukuba, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Translational Immunology Groningen (TRIGR), Education Discours Apprentissages ( EDA - EA 4071 ), Université Paris Descartes - Paris 5 ( UPD5 ), University Medical Center Groningen, Université de Strasbourg ( UNISTRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Immunologie et Pathologie ( EA2216 ), Université de Brest ( UBO ) -IFR148, CHRU Brest - Service de Rhumatologie ( CHU - BREST - Rhumato ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Homéostasie Cellulaire et Pathologies ( HCP ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -CHU Limoges, and Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille )

Subjects
Genetics and Molecular Biology (all), Male, Multivariate statistics, Psychometrics, Intraclass correlation, INDEXES ESSPRI, Biochemistry, Severity of Illness Index, B-LYMPHOCYTE STIMULATOR, RESPONSIVENESS, 0302 clinical medicine, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Immunology and Allergy, Disease Activity, Outcomes research, Sjøgren's Syndrome, Rheumatology, Immunology, Biochemistry, Genetics and Molecular Biology (all), 030212 general & internal medicine, SYSTEMIC-LUPUS-ERYTHEMATOSUS, ComputingMilieux_MISCELLANEOUS, MINIMAL DISEASE-ACTIVITY, Sjogren's Syndrome, Cohort, Sjøgren's Syndrome, Female, Humans, Reproducibility of Results, Sensitivity and Specificity, [SDV.IMM]Life Sciences [q-bio]/Immunology, medicine.medical_specialty, PRIMARY SJOGRENS-SYNDROME, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Internal medicine, Severity of illness, medicine, Journal Article, Validation Studies, 030203 arthritis & rheumatology, business.industry, HEALTH-STATUS INSTRUMENTS, Gold standard (test), RHEUMATOID-ARTHRITIS, Clinical trial, DEFINITION, Physical therapy, business, ESSDAI
Abstract

ObjectiveTo develop and validate ClinESSDAI (Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index), ie, ESSDAI without the biological domain.Patients and methodsThe 702 fictive vignettes derived from 96 real cases of primary Sjögren's syndrome of the ESSDAI development study were used. As for ESSDAI development, the physician assessment of disease activity (0–10 scale) was used as the ‘gold standard’ in a multivariate model for weighting domains, after removing the biological domain. The reliability, assessed by intraclass correlation coefficient (ICC) between ClinESSDAI and ESSDAI, explored if ClinESSDAI was equivalent to ESSDAI. Its psychometric (ie, measurement) properties were compared with that of ESSDAI in an independent cohort. Also, its use was evaluated on data of two clinical trials.ResultsIn multivariate modelling, all 11 domains remained significantly associated with disease activity, with slight modifications of some domain weights. Reliability between clinESSDAI and ESSDAI was excellent (ICC=0.98 and 0.99). Psychometric properties of clinESSDAI, disease activity levels and minimal clinically important improvement thresholds and its ability to detect change over time in clinical trials were very close to that of ESSDAI.ConclusionsClinESSDAI appears valid and very close to the original ESSDAI. This score provides an accurate evaluation of disease activity independent of B-cell biomarkers. It could be used in various circumstances: (i) in biological/clinical studies to avoid data collinearity, (ii) in clinical trials, as secondary endpoint, to detect change independent of biological effect of the drug, (iii) in clinical practice to assess disease activity for visits where immunological tests have not been done.

Published
2016
Full Text
View/download PDF

176. Introduction: History of Sjögren's Syndrome

Author

Baldini, Chiara and Bombardieri, Stefano

Subjects
History, Lachrymal glands, Immunology and Microbiology (all), Medicine (all), Sjögren's syndrome, Mikulicz syndrome, Salivary glands
Published
2016

177. Early diagnosis of primary Sjögren's syndrome : EULAR-SS task force clinical recommendations

Author

Brito-Zerón, Pilar, Theander, Elke, Baldini, Chiara, Seror, Raphaèle, Retamozo, Soledad, Quartuccio, Luca, Bootsma, Hendrika, Bowman, Simon J, Dörner, Thomas, Gottenberg, Jacques-Eric, Mariette, Xavier, Bombardieri, Stefano, de Vita, Salvatore, Mandl, Thomas, Ng, Wan-Fai, Kruize, Aike A, Tzioufas, Athanasios, Vitali, Claudio, Buyon, Jill, Izmirly, Peter, Fox, Robert, Ramos-Casals, Manuel, and Eular Sjögren Syndrome Task Force

Subjects
Research Support, Non-U.S. Gov't, Journal Article, Sjögren syndrome, anti-Ro/SS-A antibodies, systemic activity, ESSDAI, classification criteria, focal lymphocytic sialadenitis, early diagnosis, Review
Abstract

Sjögren's syndrome (SjS) is a systemic autoimmune disease that mainly affects the exocrine glands, leading to generalized mucosal dryness. However, primary SjS may initially present with non-sicca (systemic) manifestations. When these features appear before the onset of an overt sicca syndrome, we may talk of an underlying 'occult' SjS. The European League Against Rheumatism (EULAR) has promoted and supported an international collaborative study group (EULAR-SS Task Force) aimed at developing consensual recommendations to provide a homogeneous approach to the patient with primary SjS presenting with systemic involvement. This review summarizes the key factors that should be taken into account in the diagnostic approach in a patient with suspected SjS according to the main clinical patterns of presentation, and is especially focused on organ-specific systemic disease presentations, including a consensus set of recommendations in order to reach an early diagnosis. Close collaboration with the different specialties involved through a comprehensive multidisciplinary approach is essential in SjS patients presenting with systemic involvements.

Published
2016

183. Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue

Author

Quartuccio, Luca, primary, Baldini, Chiara, additional, Priori, Roberta, additional, Bartoloni, Elena, additional, Carubbi, Francesco, additional, Alunno, Alessia, additional, Gandolfo, Saviana, additional, Colafrancesco, Serena, additional, Giacomelli, Roberto, additional, Gerli, Roberto, additional, Valesini, Guido, additional, Bombardieri, Stefano, additional, and De Vita, Salvatore, additional

Published
2017
Full Text
View/download PDF

184. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome

Author

Fisher, Benjamin A, primary, Jonsson, Roland, additional, Daniels, Troy, additional, Bombardieri, Michele, additional, Brown, Rachel M, additional, Morgan, Peter, additional, Bombardieri, Stefano, additional, Ng, Wan-Fai, additional, Tzioufas, Athanasios G, additional, Vitali, Claudio, additional, Shirlaw, Pepe, additional, Haacke, Erlin, additional, Costa, Sebastian, additional, Bootsma, Hendrika, additional, Devauchelle-Pensec, Valerie, additional, Radstake, Timothy R, additional, Mariette, Xavier, additional, Richards, Andrea, additional, Stack, Rebecca, additional, Bowman, Simon J, additional, and Barone, Francesca, additional

Published
2016
Full Text
View/download PDF

185. Additional file 1: of Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus

Author

Virdis, Agostino, Tani, Chiara, Duranti, Emiliano, Vagnani, Sabrina, Carli, Linda, KĂźhl, Anja, Solini, Anna, Baldini, Chiara, Talarico, Rosaria, Bombardieri, Stefano, Taddei, Stefano, and Mosca, Marta

Abstract

Supplemental methods and results. Methods: preparation, mounting and measurements in small arteries and detection of vascular superoxide anion generation. Results: effects of HCQ on vascular reactivity in Ctrl animals. (DOC 31 kb)

Published
2015
Full Text
View/download PDF

186. Additional file 3: of Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus

Author

Virdis, Agostino, Tani, Chiara, Duranti, Emiliano, Vagnani, Sabrina, Carli, Linda, Kühl, Anja, Solini, Anna, Baldini, Chiara, Talarico, Rosaria, Bombardieri, Stefano, Taddei, Stefano, and Mosca, Marta

Abstract

Relaxation associated with acetylcholine in basal conditions (saline) or in the presence of l -NAME, diphenyleneiodinium (DPI) or both in mesenteric arteries from NZ animals at baseline and at different time points. Each point represents the mean of six experiments ± SEM. *P

Published
2015
Full Text
View/download PDF

188. Additional file 2: of Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus

Author

Virdis, Agostino, Tani, Chiara, Duranti, Emiliano, Vagnani, Sabrina, Carli, Linda, Kühl, Anja, Solini, Anna, Baldini, Chiara, Talarico, Rosaria, Bombardieri, Stefano, Taddei, Stefano, and Mosca, Marta

Abstract

Relaxation associated with acetylcholine in basal conditions (saline) or in the presence of apocynin (Apo) in mesenteric arteries from NZ animals at baseline and at different time points. Each point represents the mean of six experiments ± SEM. *P

Published
2015
Full Text
View/download PDF

189. Study Group onNeuropsychiatric Systemic Lupus Erythematosus of the Italian Society of Rheumatology. Development and validation of a new algorithm for attribution ofneuropsychiatric events in systemic lupus erythematosus

Author

Bortoluzzi, A, Scirè, Ca, Bombardieri, Stefano, Caniatti, L, Conti, F, De Vita, S, Doria, A, Ferraccioli, G, Gremese, E, Mansutti, E, Mathieu, A, Mosca, Marta, Padovan, M, Piga, M, Tincani, A, Tola, Mr, Tomietto, P, Valesini, G, Zen, M, and Govoni, M.

Published
2015

190. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Author

MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Seror, Raphaèle, Bootsma, Hendrika, Saraux, Alain, Bowman, Simon J, Theander, Elke, Brun, Johan G, Baron, Gabriel, Le Guern, Véronique, Devauchelle-Pensec, Valérie, Ramos-Casals, Manel, Valim, Valeria, Dörner, Thomas, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Solans Laqué, Roser, Mandl, Thomas, Hachulla, Eric, Sivils, Kathy L, Ng, Wan-Fai, Fauchais, Anne-Laure, Bombardieri, Stefano, Priori, Roberta, Bartoloni, Elena, Goeb, Vincent, Praprotnik, Sonja, Sumida, Takayuki, Nishiyama, Sumusu, Caporali, Roberto, Kruize, Aike A, Vollenweider, Cristina, Ravaud, Philippe, Meiners, Petra, Brito-Zerón, Pilar, Vitali, Claudio, Mariette, Xavier, EULAR Sjögren's Task Force, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Seror, Raphaèle, Bootsma, Hendrika, Saraux, Alain, Bowman, Simon J, Theander, Elke, Brun, Johan G, Baron, Gabriel, Le Guern, Véronique, Devauchelle-Pensec, Valérie, Ramos-Casals, Manel, Valim, Valeria, Dörner, Thomas, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Solans Laqué, Roser, Mandl, Thomas, Hachulla, Eric, Sivils, Kathy L, Ng, Wan-Fai, Fauchais, Anne-Laure, Bombardieri, Stefano, Priori, Roberta, Bartoloni, Elena, Goeb, Vincent, Praprotnik, Sonja, Sumida, Takayuki, Nishiyama, Sumusu, Caporali, Roberto, Kruize, Aike A, Vollenweider, Cristina, Ravaud, Philippe, Meiners, Petra, Brito-Zerón, Pilar, Vitali, Claudio, Mariette, Xavier, and EULAR Sjögren's Task Force

Published
2016

191. Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations

Author

MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Brito-Zerón, Pilar, Theander, Elke, Baldini, Chiara, Seror, Raphaèle, Retamozo, Soledad, Quartuccio, Luca, Bootsma, Hendrika, Bowman, Simon J, Dörner, Thomas, Gottenberg, Jacques-Eric, Mariette, Xavier, Bombardieri, Stefano, de Vita, Salvatore, Mandl, Thomas, Ng, Wan-Fai, Kruize, Aike A, Tzioufas, Athanasios, Vitali, Claudio, Buyon, Jill, Izmirly, Peter, Fox, Robert, Ramos-Casals, Manuel, Eular Sjögren Syndrome Task Force, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Brito-Zerón, Pilar, Theander, Elke, Baldini, Chiara, Seror, Raphaèle, Retamozo, Soledad, Quartuccio, Luca, Bootsma, Hendrika, Bowman, Simon J, Dörner, Thomas, Gottenberg, Jacques-Eric, Mariette, Xavier, Bombardieri, Stefano, de Vita, Salvatore, Mandl, Thomas, Ng, Wan-Fai, Kruize, Aike A, Tzioufas, Athanasios, Vitali, Claudio, Buyon, Jill, Izmirly, Peter, Fox, Robert, Ramos-Casals, Manuel, and Eular Sjögren Syndrome Task Force

Published
2016

192. Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study

Author

Martin Martin Luis Severino, F. Versace, M. Granata, Migliore Alberto, Adami Silvano, E. Tinazzi, Di Giuseppe Paolo, Raffaele Pellerito, P. De Sandre, Maurizio Muratore, Malavolta Nazzarena, Mathieu Alessandro, Concesi Claudia, Lunardi Claudio, Sinigaglia Luigi, Romeo Nicoletta, B. Kroegler, Del Sante Giovanni, Domenico Biasi, Laura Bazzichi, Bombardieri Stefano, Leardini Gianni, Oscar Massimiliano Epis, Pistone Giovanni, R. Russo, C. Meschini, Mazzone Antonino, Laganà Bruno, Marasini Bianca, M. Corsaro Santi, Fusaro Enrico, and C. Astolfi

Subjects
Adult, Male, medicine.medical_specialty, Rheumatoid arthritis Anti-TNF failures, Rituximab, Safety, Rheumatology, lcsh:Internal medicine, lcsh:Medicine, Arthritis, Rheumatoid, Young Adult, Quality of life, Internal medicine, medicine, Humans, Prospective Studies, Rituximab, Rheumatoid arthritis Anti-TNF failures, Safety, Adverse effect, lcsh:RC31-1245, Aged, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, business.industry, Tumor Necrosis Factor-alpha, lcsh:R, Common Terminology Criteria for Adverse Events, Middle Aged, medicine.disease, Surgery, Italy, Rheumatoid arthritis, Erythrocyte sedimentation rate, Antirheumatic Agents, Observational study, Female, business, medicine.drug
Abstract

The paper reports the results from the observational retrospective-prospective RUBINO study conducted in Italy to assess the safety of rituximab in the treatment of rheumatoid arthritis (RA) in routine clinical practice. The percentage of patients who manifested at least one grade 3 or 4 adverse event (AE) assessed by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v.3) during the observation period (primary objective) was evaluated. The percentage of patients manifesting a severe AE (SAE), clinical response to rituximab treatment, clinical remission according to disease activity score for 28 joints (DAS28) criteria, markers of disease and quality of life were also assessed. Fifty-three Italian rheumatology centers took part in the study. Patients with a diagnosis of RA and inadequate response to anti-tumor necrosis factor b (anti-TNFa) drugs were enrolled. Participating patients had previously received at least one cycle of rituximab, and treatment was still ongoing at the time of recruitment. Out of 205 patients enrolled, 60% manifested no form of AE, 14.2% had at least one grade 3 or 4 AE, and 11.2% patients reported an SAE. The overall percentage of patients manifesting AEs (40%) was lower compared to the DANCER (81% and 85%), REFLEX (85%) and RESET (85% and 69%) studies, but higher than that observed in the CERERRA registry (from 10.2% to 13.9%). This difference may be due to the shorter observation period applied in the CERERRA registry (only 12 months) compared to the RUBINO study (up to 3 years). All parameters of RA activity (erythrocyte sedimentation rate, C-reactive protein, health assessment questionnaire score, DAS28) improved significantly during the study.

Published
2014

193. Biomarkers in fibromyalgia: a review

Author

Giacomelli, Camillo, Sernissi,Francesca, Rossi,Alessandra, Bombardieri,Stefano, and Bazzichi,Laura

Subjects
humanities, Current Biomarker Findings
Abstract

Camillo Giacomelli,* Francesca Sernissi,* Alessandra Rossi, Stefano Bombardieri, Laura BazzichiRheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy *These authors contributed equally to the manuscript Abstract: Fibromyalgia is a common syndrome diagnosed by clinical criteria. The main symptom of fibromyalgia is pain, but patients frequently also complain about other nonspecific symptoms, such as headache, sleep disturbance, mood disorder, and cognitive impairment. In the light of the multifactorial origin of the disease and of the lack of objective diagnostic findings, several attempts have been made to find a reliable biomarker. For this reason, over the years, a number of patients and various biological samples have been studied, using many different approaches and techniques. Despite this, none of these studies has been able to find the proper biomarker. The aim of this review is to provide a critical overview of the current environment characterizing the search for fibromyalgia biomarkers. Keywords: genetics, proteomics, oxidative stress, fibromyalgia

Published
2014

196. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). in combination wiIh methotrexate

Author

Gseror, R, Bootsma, H, Saraux, A, Bowman, Sj, Theander, E, Brun, Jg, Baron, G, Le Guern, V, Devauchelle Pensec, V, Ramos Casals, M, Valim, V, Dörner, T, Tzioufas, A, Gottenberg, Je, Solans Laqué, R, Mandl, T, Hachulla, E, Sivils, Kl, Ng, Wf, Fauchais, Al, Bombardieri, Stefano, Priori, R, Bartoloni, E, Goeb, V, Praprotnik, S, Sumida, T, Nishiyama, S, Caporali, R, Kruize, Aa, Vollenweider, C, Ravaud, P, Meiners, P, Brito Zerón, P, Vitali, C, and Mariette, X.

Published
2014

197. Validation of the classification criteria for cryoglobulinaemic vasculitis

Author

Quartuccio, Luca Isola, Miriam Corazza, Laura Ramos-Casals, Manuel Retamozo, Soledad Ragab, Gaafar Mohamed Zoheir, Mostafa Naguib El-Menyawi, Manal Abdel-Moneim Salem, Mohamed Nabil Sansonno, Domenico Ferraccioli, Gianfranco Gremese, Elisa Tzioufas, Athanasios Voulgarelis, Michael and Vassilopoulos, Dimitris Scarpato, Salvatore Pipitone, Nicolo and Salvarani, Carlo Guillevin, Loic Terrier, Benjamin Cacoub, Patrice Filippini, Davide Saccardo, Francesco Gabrielli, Armando Fraticelli, Paolo Sebastiani, Marco Tomsic, Matija and Tavoni, Antonio Mazzaro, Cesare Pioltelli, Pietro and Nishimoto, Norihiro Scaini, Patrizia Zignego, Anna Linda and Ferri, Clodoveo Monti, Giuseppe Pietrogrande, Maurizio and Bombardieri, Stefano Galli, Massimo De Vita, Salvatore

Abstract

Objective. The aim of this study was to validate the classification criteria for cryoglobulinaemic vasculitis (CV). Methods. Twenty-three centres were involved. New patients with CV (group A) and controls, i.e. subjects with serum cryoglobulins but lacking CV based on the gold standard of clinical judgment (group B) and subjects without cryoglobulins but with clinical features that can be observed in the course of CV (group C), were studied. Positivity of serum cryoglobulins was necessary for CV classification. Sensitivity and specificity of the criteria were calculated by comparing group A vs group B. The group A vs group C comparison was done to demonstrate the possible diagnostic utility of the criteria. Results. The study included 268 patients in group A, 182 controls in group B and 193 controls in group C (small vessel vasculitis, 51.8%). The questionnaire (at least 2/3 positive answers) showed 89.0% sensitivity and 93.4% specificity; the clinical item (at least 3/4 clinical involvement) showed 75.7% sensitivity and 89.0% specificity and the laboratory item (at least 2/3 laboratory data) showed 80.2% sensitivity and 62.4% specificity. The sensitivity and specificity of the classification criteria (at least 2/3 positive items) were 89.9% and 93.5%, respectively. The comparison of group A with group C demonstrated the clinical utility of the criteria in differentiating CV from CV mimickers. Conclusion. Classification criteria for CV were validated in a second, large, international study confirming good sensitivity and specificity in a complex systemic disease.

Published
2014

199. Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center

Author

Barsotti, Simone, primary, Zampa, Virna, additional, Talarico, Rosaria, additional, Minichilli, Fabrizio, additional, Ortori, Simona, additional, Iacopetti, Valentina, additional, D'ascanio, Anna, additional, Tavoni, Antonio Gaetano, additional, Bombardieri, Stefano, additional, Mosca, Marta, additional, and Neri, Rossella, additional

Published
2016
Full Text
View/download PDF

200. Patient with Systemic Lupus Erythematosus (SLE), complex adnexal masses and ascites

Author

Lacconi, Chiara, Bulleri, Alessandra, Tavoni, Antonio, Iacconi, Pietro, Bombardieri, Stefano, and Caramella, Davide

Subjects
Lupus, Ascites, Systemic lupus erythematosus, Ovarian cancer, Health
Abstract

Table of Contents Abstract Introduction Case Report Discussion References Abstract Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect many organs. Gastrointestinal involvement is not rare and [...]

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results